Bank of Montreal Can Grows Stake in Repare Therapeutics Inc. (NASDAQ:RPTX)

Bank of Montreal Can grew its stake in Repare Therapeutics Inc. (NASDAQ:RPTX) by 5.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 110,935 shares of the company’s stock after buying an additional 5,673 shares during the period. Bank of Montreal Can owned 0.26% of Repare Therapeutics worth $366,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. XTX Topco Ltd acquired a new stake in Repare Therapeutics during the 2nd quarter worth approximately $110,000. Opaleye Management Inc. acquired a new stake in shares of Repare Therapeutics in the first quarter valued at about $318,000. Acadian Asset Management LLC increased its stake in Repare Therapeutics by 53.5% in the 1st quarter. Acadian Asset Management LLC now owns 133,893 shares of the company’s stock valued at $625,000 after purchasing an additional 46,648 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Repare Therapeutics by 30.7% in the second quarter. Renaissance Technologies LLC now owns 458,700 shares of the company’s stock valued at $1,514,000 after buying an additional 107,700 shares in the last quarter. Finally, BVF Inc. IL raised its position in Repare Therapeutics by 24.6% during the fourth quarter. BVF Inc. IL now owns 10,333,600 shares of the company’s stock worth $75,435,000 after acquiring an additional 2,041,612 shares during the last quarter. Hedge funds and other institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Trading Down 1.2 %

NASDAQ RPTX opened at $3.27 on Friday. The company’s fifty day simple moving average is $3.16 and its 200-day simple moving average is $3.47. The stock has a market cap of $138.81 million, a P/E ratio of -3.01 and a beta of 0.72. Repare Therapeutics Inc. has a 52 week low of $2.71 and a 52 week high of $8.49.

Repare Therapeutics (NASDAQ:RPTX) last released its earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.03. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 31.11%. The firm had revenue of $1.07 million during the quarter, compared to analyst estimates of $4.02 million. On average, research analysts expect that Repare Therapeutics Inc. will post -2.15 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Repare Therapeutics in a research note on Monday, September 23rd. Lifesci Capital raised shares of Repare Therapeutics to a “strong-buy” rating in a research report on Monday, July 29th.

Repare Therapeutics Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.